Aceto to launch generic for ALS treatment

June 11, 2013

Aceto Corporation, Port Washington, N.Y., announced June 11 that its generics subsidiary, Rising Pharmaceuticals Inc., Paramus, N.J., will launch the 50-mg strength of riluzole tablets.

Aceto Corporation, Port Washington, N.Y., announced June 11 that its generics subsidiary, Rising Pharmaceuticals Inc., Paramus, N.J., will launch the 50-mg strength of riluzole tablets.

Riluzole is used to treat amyotrophic lateral sclerosis (ALS) and in 2012 generated $64 million in sales, according to IMS Health. Aceto’s product is an FDA-approved version of Covis Pharma's (Switzerland) Rilutek. Rising Pharmaceuticals has launched nine generic products in 2013.